雷公藤甲素下调CT26结肠癌细胞保罗样蛋白激酶-1水平发挥抑瘤活性

doi:10.16098/j.issn.0529-1356.2025.01.001

解剖学报 ›› 2025, Vol. 56 ›› Issue (1): 4-10.doi: 10.16098/j.issn.0529-1356.2025.01.001

• 肿瘤学专栏 • 下一篇

雷公藤甲素下调CT26结肠癌细胞保罗样蛋白激酶-1水平发挥抑瘤活性

卢智豪李雪铭姜艳玲赵旭冯婧李健^*

北京中医药大学中医学院组织学胚胎学教研室，北京100029

收稿日期:2024-04-16 修回日期:2024-07-16 出版日期:2025-02-06 发布日期:2025-02-06
通讯作者: 李健 E-mail:lijiancn922@126.com
基金资助:

Effect of triptolide on the expression of Polo-like kinase -1 in CT26 colon cancer and its antitumor activity

LU Zhi-hao LI Xue-ming JIANG Yan-ling ZHAO Xu FENG Jing LI Jian^*

Histology and Embryology Department, School of Traditional Chinese Medicine, Beijing University of Traditional Chinese Medicine, Beijing 100029, China

Received:2024-04-16 Revised:2024-07-16 Online:2025-02-06 Published:2025-02-06
Contact: LI Jian E-mail:lijiancn922@126.com

摘要/Abstract

摘要：

目的探讨雷公藤甲素抗CT26结肠癌及其对保罗样蛋白激酶-1(PLK-1）蛋白表达的影响。方法清洁级BALB/c小鼠40只，每只小鼠移植1×10⁶个CT26细胞到右前肢背侧皮下，建立荷瘤小鼠模型，并随机分4组，即肿瘤模型组（溶剂对照）、阳性药组［奥沙利铂，5mg/（kg·d）］、雷公藤甲素低剂量组［50μg/（kg·d）］和雷公藤甲素高剂量组［100μg/（kg·d）］，腹腔注射给药（隔日1次，共10次）。同时评估药物体外作用对CT26细胞增殖、迁移、侵袭及有丝分裂的影响。结果雷公藤甲素能显著抑制CT26结肠癌细胞增殖、迁移和侵袭，干扰肿瘤细胞有丝分裂前期中心体分离和染色体正确排布；雷公藤甲素和PLK-1蛋白结合能为-7.1 kcal/mol，其能下调CT26细胞内PLK-1的表达。结论雷公藤甲素通过下调PLK-1的表达发挥抗CT26结肠癌的药理作用。

关键词: 雷公藤甲素, CT26细胞系, 移植瘤模型, 保罗样蛋白激酶-1, 免疫组织化学, 小鼠

Abstract:

Objective To investigate the antitumor effects of triptolide against CT26 colon cancer and its impact on the expression of Polo-like kinase-1 (PLK-1) protein. Methods Forty clean grade BALB/c mice, each mouse was implanted with 1×10⁶ CT26 cells into the dorsal side of the right forelimb to establish a tumor-bearing mouse model. Experimental animals were randomly divided into four groups, the tumor model group (saline control), the positive drug group ［oxaliplatin, 5mg/(kg·d)］, the low-dose triptolide group ［50μg/(kg·/d)］, and the high-dose triptolide group ［100μg/(kg·d)］. The drugs were administered through intraperitoneal injection (10 times in total, once every other day). The in vitro effects of the drugs on the proliferation, migration, invasion, and mitosis of CT26 cells were also assessed. Results Triptolide significantly inhibited the proliferation, migration, and invasion of CT26 colon cancer cells, and disrupted the separation of centrosomes and the correct arrangement of chromosomes during the prophase of mitosis in tumor cells. The binding energy of triptolide and PLK-1 protein was -7.1 kcal/mol, and it could down-regulate the expression of PLK-1 in CT26 cells. Conclusion Triptolide exerts its antitumor effects against CT26 colon cancer by downregulating the expression of PLK-1.

Key words: Triptolide, CT26 cell line, Tumor-bearing model, Polo-like kinase-1, Immunohistochemistry, , Mouse

中图分类号:

R685.4

卢智豪李雪铭姜艳玲赵旭冯婧李健. 雷公藤甲素下调CT26结肠癌细胞保罗样蛋白激酶-1水平发挥抑瘤活性[J]. 解剖学报, 2025, 56(1): 4-10.

LU Zhi-hao LI Xue-ming JIANG Yan-ling ZHAO Xu FENG Jing LI Jian. Effect of triptolide on the expression of Polo-like kinase -1 in CT26 colon cancer and its antitumor activity[J]. Acta Anatomica Sinica, 2025, 56(1): 4-10.

参考文献

［1］Qin FX, Tian LF, Wang ZhE, et al. Exploration of the mechanism of tripterygium wilfordii in treating colon cancer based on network pharmacology and molecular docking technology ［J］. Chinese Journal of Modern Drug Applications, 2023, 17(24):141-147. (in Chinese)

秦方序, 田丽凤, 王知恩, 等. 基于网络药理学与分子对接技术探讨雷公藤治疗结肠癌的作用机制［J］.中国现代药物应用, 2023,17(24):141-147.

［2］Zhang TJ, Han S, Zhang W, et al. Triptolide promotes apoptosis of colon cancer CT26 cells by inducing autophagy ［J］. Acta Anatomica Sinica, 2016, 47(6):774-779. (in Chinese)

张天娇, 韩森, 张玮, 等. 雷公藤甲素通过诱导细胞自噬促进结肠癌 CT26 细胞死亡［J］. 解剖学报, 2016, 47(6):774-779.

［3］Li C, Li Z, Zhang T, et al. 1H NMR-based metabolomics reveals the antitumor mechanisms of triptolide in BALB/c mice bearing CT26 tumors［J］. Front Pharmacol, 2019, 11(10):1175.

［4］Shakeel I, Basheer N, Hasan GM, et al. Polo-like kinase 1 as an emerging drug target: structure, function and therapeutic implications ［J］. J Drug Target, 2021, 29(2):168-184.

［5］Kumar S, Kim J. PLK-1 targeted inhibitors and their potential against tumorigenesis ［J］. Biomed Res Int, 2015, 2015: 705745.

［6］Cui JT, Lu AG, Wang TF, et al. Expression of Polo-like kinase 1 in colorectal cancer tissues and its role in the proliferation of colorectal cancer cells［J］. Journal of Surgery Comcepts & Practice, 2010, 15(5):536-542. (in Chinese)

崔江涛, 陆爱国, 王廷峰, 等. Polo样激酶1在结肠直肠癌组织中的表达及其在结肠直肠癌细胞增殖中的作用［J］. 外科理论与实践, 2010, 15(5):536-542.

［7］Ahn DH, Barzi A, Ridinger M, et al. Onvansertib in combination with FOLFIRI and bevacizumab in second-line treatment of KRAS-mutant metastatic colorectal cancer: a phase 1b clinical study［J］. Clin Cancer Res, 2024, 30(10):2039-2047.

［8］Gaillard T. Evaluation of autodock and autodock vina on the CASF-2013 benchmark［J］. J Chem Inf Model, 2018, 58 (8):1697-1706.

［9］Corson TW, Crews CM. Molecular understanding and modern application of traditional medicines: triumphs and trials［J］. Cell, 2007,130(5): 769-774.

［10］Zhang J, Huang Q, Zhao R, et al. A network pharmacology study on the tripteryguim wilfordii Hook for treatment of Crohn’s disease［J］. BMC Complement Med Ther, 2020, 20(1):95.

［11］Feng K, Li X, Bai Y,et al. Mechanisms of cancer cell death induction by triptolide: a comprehensive overview［J］. Heliyon, 2024,10(2): e24335.

［12］Zitouni S, Nabais C, Jana SC, et al. Polo-like kinases: structural variations lead to multiple functions［J］. Nat Rev Mol Cell Biol, 2014, 15(7):433-453.

［13］Raab M, Sanhaji M, Matthess Y, et al. PLK-1 has tumor-suppressive potential in APC-truncated colon cancer cells［J］. Nat Commun, 2018(1),9:1106.

［14］Wang MW, Li Z, Chen LH, et al. Polo-like kinase 1 as a potential therapeutic target and prognostic factor for various human malignancies: a systematic review and meta-analysis［J］. Front Oncol, 2022,12:917366.

［15］Ali NM, Akhtar MN, Ky M, et al. 3Flavokawain derivative FLS induced G2/M arrest and apoptosis on breast cancer MCF-7 cell line［J］. Drug Des Devel Ther, 2016, 10:1897-1907.

［16］Su S, Chhabra G, Singh CK, et al. PLK-1 inhibition-based combination therapies for cancer management［J］. Transl Oncol, 2022,16:101332.

[1]	冷历歌杨冠雄王泽恩陈椅乔治良胡庆中王明炎田风. 基于fMOST高分辨率3D重建系统的C57BL/6小鼠模型内脏神经系统的形态学观察[J]. 解剖学报, 2025, 56(1): 114-119.
[2]	王长宗洪玲玲陈怡园. 依达拉奉调节Notch/Hes-1信号通路对慢性心力衰竭大鼠心肌损伤的影响[J]. 解剖学报, 2025, 56(1): 95-104.
[3]	杨云孙攀文许亚平郭志坤. 小鼠冠状动脉粥样硬化区域炎性因子对干细胞迁移的调控作用[J]. 解剖学报, 2024, 55(5): 565-572.
[4]	仝森罗世翠杨秋琼宋波杨榆青武俊紫 . 川陈皮素对糖尿病肾脏损伤大鼠血小板活化因子的调节作用[J]. 解剖学报, 2024, 55(5): 595-603.
[5]	陈培陈小菊杜竺蔓汪操会 . 贝母素甲改善脂多糖联合烟雾诱导小鼠慢性阻塞性肺疾病的机制[J]. 解剖学报, 2024, 55(2): 215-221.
[6]	袁蕾杨智伟杨惠刘政海何洁万炜. 三七总皂苷抑制小鼠星形胶质细胞活化缓解完全弗氏佐剂所致炎性痛 [J]. 解剖学报, 2024, 55(1): 25-31.
[7]	郑丽平刘霞杜晓华吴亚娟刘珊珊 . 脑源性神经营养因子在牦牛与黄牛端脑不同区域的表达与分布 [J]. 解剖学报, 2024, 55(1): 10-16.
[8]	刘丽平朱梦妮徐慧 . 白细胞介素6对脂多糖诱导所致类子痫前期大鼠有核红细胞的影响 [J]. 解剖学报, 2023, 54(6): 722-729.
[9]	梁盼盼禹爱梅杜静寇文辉王欢欢宋爱霞. 基于c-Jun氨基末端激酶/p38丝裂原活化蛋白激酶信号通路探讨阿魏酸钠对偏头痛大鼠炎症反应的抑制作用[J]. 解剖学报, 2023, 54(6): 652-659.
[10]	刘叶楚亚楠徐岑璐何佳澄苏炳银太颢然. Roscovitine挽救帕金森病小鼠相关脑区神经元丢失和神经炎症[J]. 解剖学报, 2023, 54(6): 635-643.
[11]	阎锟武筱林刘英娟葛科立任雷鸣李红云 . 脑蛋白水解物-Ⅰ对帕金森病小鼠肠道菌群的调节作用[J]. 解剖学报, 2023, 54(5): 497-504.
[12]	庄海容吴子东陈雪红李成军. 舒洛地特对大鼠糖尿病视网膜病变的修复及MAPK通路的调节作用[J]. 解剖学报, 2023, 54(4): 392-399.
[13]	于华婧魏路阳刘姗姗管成剑张忠涛. MLLT1超伸长复合亚基在肝细胞癌发生发展中的作用及其临床意义[J]. 解剖学报, 2023, 54(4): 425-433.
[14]	王潇李梁崔成立蔡志平于畅张立佳 . 耐力运动联合间歇性冷刺激促进大鼠白色脂肪组织棕色化[J]. 解剖学报, 2023, 54(3): 348-356.
[15]	张沂洲李莎米世雄左洪春张倩倩李晗琳雷梓晗张东泽崔慧先. 雌二醇经雌激素受体调控分拣蛋白相关受体A对小鼠海马神经元树突棘密度和突触蛋白表达的影响[J]. 解剖学报, 2023, 54(3): 261-268.

雷公藤甲素下调CT26结肠癌细胞保罗样蛋白激酶-1水平发挥抑瘤活性

Effect of triptolide on the expression of Polo-like kinase -1 in CT26 colon cancer and its antitumor activity

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价